Share

Contacts

Quotes

We are very excited about the continued progress and promising early data of ADC-1013. The data indicate that it is well tolerated at clinically relevant doses. There is clear evidence supporting activation of CD40 receptors, which together with the clinical observations gives us increased confidence for the continued clinical development of ADC-1013.
Per Norlén, CEO at Alligator Bioscience
I am very enthusiastic about the extended collaboration with Alligator. Its 4-1BB drug candidates provide great new treatment opportunities within immuno-oncology. The fact that 4-1BB is upregulated on tumor-specific T cells, together with its capacity to promote survival, expansion and functional activity of several immune cells involved in tumor eradication, makes 4-1BB a uniquely appealing target for immunotherapy of cancer.
Professor Ignacio Melero, Universidad de Navarra, Spain.
We are very fortunate to have Professor Melero as a research collaborator. He is a world leading expert in the field of 4-1BB and immunotherapy and his scientific guidance will be extremely valuable both for our pipeline projects, and to help fulfill our ambition to deliver first and best-in-class products to patients.
Per Norlén, CEO of Alligator Bioscience
With CMC and IND enabling activities underway, our partnership with Aptevo is moving ahead rapidly. Having worked collaboratively to design and engineer ALG.APV-527, we are pleased to now announce its advancement into preclinical development. This bispecific antibody brings tumor directed immunotherapy to the next level. By making the immune activation dependent on binding to a tumor antigen we have created a candidate drug with potential for improved efficacy and fewer side effects.
Per Norlén, Chief Executive Officer of Alligator Bioscience
Pick a time period -
There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe